Crinetics Pharmaceuticals Inc. (CRNX)
NASDAQ · Healthcare
Crinetics Pharmaceuticals Inc. EBITDA 2016–2025
Crinetics Pharmaceuticals Inc. annual/quarterly ebitda history and growth rate from 2016 to 2026. EBITDA stands for Earnings Before Interest, Taxes, Depreciation and Amortization. It is widely used as a measure of core operational profitability.
- Crinetics Pharmaceuticals Inc. ebitda for the quarter ending March 31, 2026 was -139.2 M, a 26.01% increase year-over-year.
- Crinetics Pharmaceuticals Inc. ebitda for the twelve months ending March 31, 2026 was -370.4 M, a 342.74% increase year-over-year.
- Crinetics Pharmaceuticals Inc. annual ebitda for 2025 was -512.9 M, a 52.62% increase from 2024.
- Crinetics Pharmaceuticals Inc. annual ebitda for 2024 was -336.1 M, a 51.71% increase from 2023.
- Crinetics Pharmaceuticals Inc. annual ebitda for 2023 was -221.5 M, a 32.72% increase from 2022.
- Crinetics Pharmaceuticals Inc. annual ebitda for 2022 was -166.9 M.
EBITDA
ANNUAL · $B
QUARTERLY · $B
YEAR-OVER-YEAR GROWTH · %
Crinetics Pharmaceuticals Inc. EBITDA — FAQ
Crinetics Pharmaceuticals Inc. (CRNX) ebitda over the last 10 years — annual and quarterly figures with year-over-year growth and charts.
Where can I see CRNX's ebitda history?
The chart and table above show Crinetics Pharmaceuticals Inc.'s ebitda by year and by quarter, including the growth rate.